Zobrazeno 1 - 10
of 180
pro vyhledávání: '"L. A. Pierce"'
Autor:
L. Ross Pierce
Publikováno v:
Heliyon, Vol 10, Iss 11, Pp e31183- (2024)
Clinical benefit of Alpha1-Proteinase Inhibitor (Human) (A1-PI) products for Alpha1-antitrypsin deficiency (AATD) is uncertain, based on a systematic review of observational studies and randomized controlled trials (RCTs) in AATD of Alpha1-Proteinase
Externí odkaz:
https://doaj.org/article/5306433dcea549a29270a8ff19d00b90
Autor:
Peter J. Klauck, Stacey M. Bagby, Anna Capasso, Erica L. Bradshaw-Pierce, Heather M. Selby, Anna Spreafico, John J. Tentler, Aik Choon Tan, Jihye Kim, John J. Arcaroli, Alicia Purkey, Wells A. Messersmith, Keisuke Kuida, S. Gail Eckhardt, Todd M. Pitts
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-12 (2018)
Abstract Background Polo-like kinase 1 (Plk1) is a serine/threonine kinase that is a key regulator of multiple stages of mitotic progression. Plk1 is upregulated in many tumor types including colorectal cancer (CRC) and portends a poor prognosis. TAK
Externí odkaz:
https://doaj.org/article/d4dd779ae0964c9eb1a995ae2b3952c9
PDF - 80KB, Figure S1. Schematic representation of a PBPK model for docetaxel with IP administration. Table S1. Mouse Organ Weight Parameters Table S2. PBPK Model Parameters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a1fe395a25d6839b3fa4cd3e68791a9
https://doi.org/10.1158/1535-7163.22484991
https://doi.org/10.1158/1535-7163.22484991
Autor:
Paolo Vicini, Erica L. Bradshaw-Pierce, Judy Lucas, Gang Li, Shinji Yamazaki, Chandra Vage, Ravi Visswanathan, Xiaoying Chen, Mary E. Spilker
Trastuzumab CRD Calculation Details
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6432acf19612f1e3aef15c601f41b2f
https://doi.org/10.1158/1078-0432.22466916.v1
https://doi.org/10.1158/1078-0432.22466916.v1
Autor:
Paolo Vicini, Erica L. Bradshaw-Pierce, Judy Lucas, Gang Li, Shinji Yamazaki, Chandra Vage, Ravi Visswanathan, Xiaoying Chen, Mary E. Spilker
Description of common pharmacokinetic parameters used in the CRD calculations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4448f1b2e533650c26b835eddec72a09
https://doi.org/10.1158/1078-0432.22466919.v1
https://doi.org/10.1158/1078-0432.22466919.v1
Autor:
Paolo Vicini, Erica L. Bradshaw-Pierce, Judy Lucas, Gang Li, Shinji Yamazaki, Chandra Vage, Ravi Visswanathan, Xiaoying Chen, Mary E. Spilker
Dasatinib CRD Calculation Details
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ba03f7ddef0141746657d3d973194d4
https://doi.org/10.1158/1078-0432.22466925.v1
https://doi.org/10.1158/1078-0432.22466925.v1
Autor:
Paolo Vicini, Erica L. Bradshaw-Pierce, Judy Lucas, Gang Li, Shinji Yamazaki, Chandra Vage, Ravi Visswanathan, Xiaoying Chen, Mary E. Spilker
Vismodegib CRD Calculation Details
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa49ae495587c32c40c82b321820aa77
https://doi.org/10.1158/1078-0432.22466913
https://doi.org/10.1158/1078-0432.22466913
Autor:
Paolo Vicini, Erica L. Bradshaw-Pierce, Judy Lucas, Gang Li, Shinji Yamazaki, Chandra Vage, Ravi Visswanathan, Xiaoying Chen, Mary E. Spilker
Purpose: The translation of nonclinical oncology studies is a subject of continuous debate. We propose that translational oncology studies need to optimize both pharmacokinetic (drug exposure) and pharmacodynamic (xenograft model) aspects. While impr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49f3b5251c6cb1f7d159009e3d3a9100
https://doi.org/10.1158/1078-0432.c.6526479.v1
https://doi.org/10.1158/1078-0432.c.6526479.v1
Autor:
Paolo Vicini, Erica L. Bradshaw-Pierce, Judy Lucas, Gang Li, Shinji Yamazaki, Chandra Vage, Ravi Visswanathan, Xiaoying Chen, Mary E. Spilker
Full Description with references for the data included in Figure 4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4150efa684d74c6679f80a41d19a9ac1
https://doi.org/10.1158/1078-0432.22466922.v1
https://doi.org/10.1158/1078-0432.22466922.v1
Docetaxel, usually administered according to maximum tolerated dose (MTD), can inhibit endothelial cell proliferation at low nanomolar concentrations. Docetaxel may exert antiangiogenic effects if dosed so plasma levels are maintained at low nanomola
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eabe5b20cbbd445bbc6e7d9ed0c533c
https://doi.org/10.1158/1535-7163.c.6531705
https://doi.org/10.1158/1535-7163.c.6531705